|Mr. Paul F. Truex MBA||Exec. Chairman||626.32k||4.36k||48|
|Mr. John Craig Thompson||Chief Exec. Officer, Pres and Director||533.55k||N/A||50|
|Ms. May Liu||Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer||373.44k||N/A||41|
|Dr. Charles V. Olson D.Sc.||CTO & Sr. VP||381.4k||N/A||60|
|Dr. William R. Shanahan Jr., M.D., J.D.||Chief Medical Officer and Sr. VP||195.95k||N/A||68|
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, CA, US.
Anthera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 9; Compensation: 8.